Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00400348 | Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer | PHASE2 | COMPLETED | 18 | — | — | Oct 1, 2006 | Nov 1, 2008 | Nov 25, 2008 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Panzem Nanocrystal Colloidal Dispersion (NCD) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of protected health information. 2. Have histologically-confirmed: * epithelial ovarian cancer or * primary peritoneal carcinomatosis or * fallopian tube cancer. Enrollment of patients with clear cell hist...